Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

AstraZeneca PLC (AZN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
66.41+0.20 (+0.30%)
At close: 04:00PM EDT
66.03 -0.38 (-0.57%)
After hours: 07:28PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close66.21
Open66.46
Bid66.38 x 2200
Ask66.77 x 1300
Day's Range66.29 - 67.32
52 Week Range53.63 - 71.70
Volume6,467,777
Avg. Volume7,410,050
Market Cap205.8B
Beta (5Y Monthly)0.12
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.44 (2.22%)
Ex-Dividend DateFeb 24, 2022
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AZN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Astrazeneca PLC
    Analyst Report: AstraZeneca PLCA merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
    Rating
    Fair Value
    Economic Moat
    21 days agoMorningstar
View more
  • Reuters

    FOCUS-U.S. Task Force to consider routine kidney disease screening as new drugs available

    An influential U.S. panel has added screening for chronic kidney disease (CKD) to its list of preventive services under active consideration, the group's chair told Reuters, a move that could help identify patients eligible for new drugs that treat the disease earlier. The U.S. Preventive Services Task Force (USPSTF) last addressed the issue in 2012, finding insufficient evidence to assess routine screening for CKD in asymptomatic adults.

  • Reuters

    Indian vaccine giant Serum plans African plant in global expansion

    The Serum Institute of India (SII), the world's biggest vaccine maker, is considering setting up its first manufacturing plant in Africa as it looks to expand globally after its success in selling COVID-19 shots, its CEO told Reuters on Monday. Africa was the only continent that did not have its own manufacturing capacity for COVID shots during the worst phases of the pandemic in the last two years, leaving it at the mercy of suppliers from overseas, including the SII.

  • Reuters

    RPT-FOCUS-U.S. Task Force to consider routine kidney disease screening

    An influential U.S. panel has added screening for chronic kidney disease (CKD) to its list of preventive services under active consideration, the group's chair told Reuters, a move that could help identify patients eligible for new drugs that treat the disease earlier. The U.S. Preventive Services Task Force (USPSTF) last addressed the issue in 2012, finding insufficient evidence to assess routine screening for CKD in asymptomatic adults. The change has not been announced in any public forums, a USPSTF spokesperson confirmed.

Advertisement
Advertisement